Breast cancer is not one single disease. Some forms are rare and aggressive. This report focuses on neuroendocrine breast cancer and triple-negative breast cancer. These types are hard to treat because they do not respond to standard hormone therapies. A 71-year-old postmenopausal woman faced this specific challenge. She needed a new way to fight the cancer after her disease returned.
Doctors gave her a plan that combined two chemotherapy drugs with an immunotherapy drug. The chemotherapy drugs were paclitaxel and cisplatin. The immunotherapy drug was pembrolizumab. She received this treatment every three weeks for six cycles. The goal was to stop the cancer from growing and coming back.
Twelve months after finishing treatment, she remains disease-free. There is no evidence that the cancer has returned. The treatment was well tolerated. She experienced only minor side effects, which are common and manageable. She did not stop the treatment early due to severe problems.
This report involves only one person. It is a case report. This means the evidence is early and serves as a hypothesis. It suggests this combination might work for rare, high-grade subtypes. However, it is not yet a standard of care. More research is needed to confirm these results before doctors recommend it widely.